Lipid-Lowering Therapy is Related to Inflammatory Markers and 3-Year Mortality in Patients With Critical Limb Ischemia.

Nazim Isma, Jamal Barani, Ingrid Mattiason, Bengt Lindblad, Anders Gottsäter

Research output: Contribution to journalArticlepeer-review

Abstract

To evaluate relationships between lipid-lowering therapy, inflammation, and 3-year mortality in critical limb ischemia (CLI), 259 consecutive CLI patients underwent evaluation of medication, tumor necrosis factor-alpha, interleukin-6 (IL6), neopterin, high-sensitivity C-reactive protein (hs-CRP), 8-epi-PGF2alpha, and endothelin-1. Mortality was assessed after 3 years. Sixty-one patients (24%) were on lipid-lowering therapy and 59 patients (97%) on statins. Patients on lipid-lowering therapy were younger and showed lower low-density lipoprotein cholesterol, hs-CRP, and IL-6 levels than patients without therapy. Three-year survival was higher among patients on lipid-lowering therapy. In logistic regression, the effect of lipid-lowering therapy on 3year survival was significant with inflammatory markers entered into the model one by one but disappeared when all inflammatory markers were entered into the model together. In conclusion, hs-CRP and IL-6 levels were lower and 3-year survival was higher in CLI patients on lipid-lowering therapy.
Original languageEnglish
Pages (from-to)542-548
JournalAngiology
Volume59
DOIs
Publication statusPublished - 2008

Subject classification (UKÄ)

  • Cardiac and Cardiovascular Systems

Fingerprint

Dive into the research topics of 'Lipid-Lowering Therapy is Related to Inflammatory Markers and 3-Year Mortality in Patients With Critical Limb Ischemia.'. Together they form a unique fingerprint.

Cite this